BR0116123A - Carbazóis antitumorais - Google Patents

Carbazóis antitumorais

Info

Publication number
BR0116123A
BR0116123A BR0116123-7A BR0116123A BR0116123A BR 0116123 A BR0116123 A BR 0116123A BR 0116123 A BR0116123 A BR 0116123A BR 0116123 A BR0116123 A BR 0116123A
Authority
BR
Brazil
Prior art keywords
carbazoles
antitumor
medicine
relates
carbazois
Prior art date
Application number
BR0116123-7A
Other languages
English (en)
Inventor
Murray Herbert Gibson Munro
John Wilson Blunt
Sylvia Urban
Dolores Garcia Gravalos
Original Assignee
Pharma Mar Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharma Mar Sa filed Critical Pharma Mar Sa
Publication of BR0116123A publication Critical patent/BR0116123A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/80—[b, c]- or [b, d]-condensed
    • C07D209/82—Carbazoles; Hydrogenated carbazoles
    • C07D209/88—Carbazoles; Hydrogenated carbazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Abstract

"CARBAZóIS ANTITUMORAIS". A invenção provê um composto da fórmula (I). Esta invenção refere-se a compostos heterocíclicos. Ela refere-se ainda a métodos para sua preparação, composições contendo-os e seu uso como um medicamento, particularmente como medicamento para o tratamento e profilaxia de câncer.
BR0116123-7A 2000-12-13 2001-12-13 Carbazóis antitumorais BR0116123A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0030417.0A GB0030417D0 (en) 2000-12-13 2000-12-13 An anticancer lead compound isolated from a New Zealand ascidian
PCT/GB2001/005523 WO2002048107A1 (en) 2000-12-13 2001-12-13 Antitumoral carbazoles

Publications (1)

Publication Number Publication Date
BR0116123A true BR0116123A (pt) 2003-10-14

Family

ID=9905016

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0116123-7A BR0116123A (pt) 2000-12-13 2001-12-13 Carbazóis antitumorais

Country Status (11)

Country Link
US (1) US7135494B2 (pt)
EP (1) EP1349837A1 (pt)
JP (1) JP2004518650A (pt)
AU (1) AU2002217266A1 (pt)
BR (1) BR0116123A (pt)
CA (1) CA2431107A1 (pt)
GB (1) GB0030417D0 (pt)
IL (1) IL156372A0 (pt)
MX (1) MXPA03005374A (pt)
NZ (1) NZ526399A (pt)
WO (1) WO2002048107A1 (pt)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8530496B2 (en) 2008-07-08 2013-09-10 Trustees Of Dartmouth College Compositions and methods for treating cancer
US8765781B2 (en) * 2008-07-08 2014-07-01 Trustees Of Dartmouth College Bis-carbazole DNA intercalating agents for antitumor therapy
US8975274B2 (en) 2011-09-20 2015-03-10 Trustees Of Dartmouth College Compositions and methods for treating cancer
SG10201704588XA (en) 2012-09-25 2017-07-28 Chugai Pharmaceutical Co Ltd Ret inhibitor
CA2946518C (en) 2014-04-25 2022-07-26 Chugai Seiyaku Kabushiki Kaisha Preparation containing tetracyclic compound at high dose
TWI752901B (zh) 2015-01-16 2022-01-21 日商中外製藥股份有限公司 合併用醫藥
JOP20190254A1 (ar) 2017-04-27 2019-10-27 Pharma Mar Sa مركبات مضادة للأورام
CA3107270A1 (en) 2018-09-04 2020-03-12 Chugai Seiyaku Kabushiki Kaisha Method for producing tetracyclic compound
WO2023220558A1 (en) * 2022-05-09 2023-11-16 Institute For Cancer Research D/B/A The Research Institute Of Fox Chase Cancer Center Combination of curaxins and immune checkpoint inhibitors for treating cancer

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0331257A (ja) 1989-06-28 1991-02-12 Kissei Pharmaceut Co Ltd インドール誘導体の製造方法
CA2108889A1 (en) 1991-05-29 1992-11-30 Robert Lee Dow Tricyclic polyhydroxylic tyrosine kinase inhibitors
JPH08157475A (ja) 1994-11-29 1996-06-18 Kissei Pharmaceut Co Ltd １−ヒドロキシインドール誘導体

Also Published As

Publication number Publication date
CA2431107A1 (en) 2002-06-20
IL156372A0 (en) 2004-01-04
US7135494B2 (en) 2006-11-14
JP2004518650A (ja) 2004-06-24
WO2002048107A1 (en) 2002-06-20
AU2002217266A1 (en) 2002-06-24
MXPA03005374A (es) 2004-03-26
US20040072890A1 (en) 2004-04-15
GB0030417D0 (en) 2001-01-24
EP1349837A1 (en) 2003-10-08
NZ526399A (en) 2005-02-25

Similar Documents

Publication Publication Date Title
HK1069169A1 (en) Substituted tetracyclic pyrroloquinolone derivatives useful as phosphodiesterase inhibitors
PL367682A1 (en) Dolastatin 10 derivatives
BR9911482A (pt) Composto, composição farmacêutica, uso do composto, e, processos para o tratamento ou profilaxia de doenças inflamatórias, e para a preparação de um composto
CY1107074T1 (el) Συνθεση εναντιομερων 4-αμινο-θαλιδομιδης
NO20050525L (no) Benzimidazol-1-yl-tiofenforbindelser for behandling av cancer
RS20050522A (en) Protein kinase inhibiting tricyclic compounds that increase the effects of anti-neoplastic agents and therapeutic radiation
AU2003228770A8 (en) Substituted pyrazolopyrimidines
ATE296826T1 (de) Pyrazolo(1,5)pyridinderivate
GB0112348D0 (en) Compounds
MY128924A (en) Novel compounds
BR0309342A (pt) Composto, composição farmacêutica, uso de um composto, e, método de tratamento ou profilaxia de doenças ou condições humanas
ATE358668T1 (de) Drogen zur behandlung maligner tumoren
BR0309343A (pt) Composto, composição farmacêutica, uso de um composto, e, método de tratamento ou profilaxia de doenças ou condições humanas
BR0215151A (pt) Derivados de azaindolilalquilamina como ligandos de 5-hidroxitriptamina-6
ES2243579T3 (es) Derivados de pirazolopirideno.
MXPA04002042A (es) Compuestos de bencimidazol sustituidos y su uso para el tratamiento del cancer.
MXPA04004606A (es) Venenos de topoisomerasa solubilizados.
DK1056704T3 (da) Antitumormidler
ATE302203T1 (de) Pyrazolopyrimidin- und pyrazolotriazinderivate und diese enthaltende pharmazeutische zubereitungen
BR0311491A (pt) Composto, composição farmacêutica, uso de um composto, e, método terapêutico para tratar câncer em um mamìfero
BR0116123A (pt) Carbazóis antitumorais
MXPA04000531A (es) Acilsemicarbazidas como inhibidores de cinasa dependiente de ciclina utiles como agentes anti-cancer y anti-proliferativos.
MXPA04005809A (es) Inhibidores de proteinas quinasas.
AU2002248531A1 (en) Pyrazolopyriadine derivatives
AU2002357740A1 (en) Pyrazolo-pyridine derivatives as antiherpes agents

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE 7A. E 8A. ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 DA RPI 2021 DE 29/09/2009.